Dr Dave Cole - Publications

Journal Publications

2017

70) Structural mechanism underpinning cross-reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase reverse transcriptase.

Cole DK, van den Berg HA, Lloyd A, Crowther MD, Beck K, Ekeruche-Makinde J, Miles JJ, Bulek AM, Dolton G, Schauenburg AJ, Wall A, Fuller A, Clement M, Laugel B, Rizkallah PJ, Wooldridge L and Sewell AK.

Journal of Biological Chemistry. In press.

69) Using X-ray crystallography, biophysics and functional assays to determine the mechanisms governing T cell receptor recognition of cancer antigens.

MacLachlan BJ, Greenshields-Watson A, Mason GH, Schauenburg AJ, Bianchi V, Rizkallah PJ, Sewell AK, Fuller A and Cole DK.

Journal of Visualized Experiments. In press.

2016

68) Paediatric non-progression following grandmother-to-child HIV transmission.

Tsai MH, Muenchhoff M, Adland E, Carlqvist A, Roider J, Cole DK, Sewell AK, Carlson J, Ndung'u T, Goulder PJ.

Retrovirology. 2016 Sep 8;13(1):65. doi: 10.1186/s12977-016-0300-y.

67) Hotspot autoimmune T-cell receptor binding to pathogen and insulin peptides.

Cole DK, Bulek AM, Dolton G, Schauenberg AJ, Szomolay B, Rittase W, Trimby A, JothikumaR P, Fuller A, Skowera A, Rossjohn J, Zhu C, Miles JJ, Peakman M, Wooldridge L, Rizkallah PJ and Sewell AK.

Journal of Clinical Investigations. 2016 Jun 1;126(6):2191-204. doi: 10.1172/JCI85679. Epub 2016 May 16.

66) A molecular switch abrogates gp100 TCR-targeting of a human melanoma antigen.

Bianchi V, Bulek A, Fuller A, Lloyd A, Attaf M, Rizkallah PJ, Dolton G, Sewell AK and Cole DK.

Journal of Biological Chemistry. 2016 Feb 25. pii: jbc.M115.707414.

65) T-cell libraries allow simple parallel procurement of multiple peptide-specific human T-cell clones.

Theaker SM, Rius C, Greenshields-Watson A, Trimby A, Fuller A, Miles JJ, Cole DK, Peakman M, Sewell AK and Dolton G.

Journal of Immunological Methods. 2016 Mar;430:43-50. doi: 10.1016/j.jim.2016.01.014. Epub 2016 Jan 28.Impact Factor 2.2.

64) Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, Le Provost GS, Todorov P, Baston E, Hickman E, Mahon T, Hassan N, Vuidepot A, Sami M, Jakobsen BK, and Cole DK.

Scientific Reports. 2016 Jan 13;6:18851. doi: 10.1038/srep18851.

63) Enhanced detection of antigen-specific CD4+ T-cells using altered peptide flanking residue pMHC-II multimers.

Holland CJ, Dolton G, Scurr M, Ladell K, Schauenburg AJA, Miners K, Madura M, Sewell AK, Price DA, Godkin AJ and Cole DK.

Journal of Immunology. 2015. Nov 9. pii: 1402787.

2015

62) The impact of HLA-class I and EBV-latency-II antigen-specific CD8+ T-cells on the pathogenesis of EBV+ Hodgkin Lymphoma.

Jones K, Wockner L, Brennan RM, Keane C, Chattopadhyay PK, Roederer M, Price DA, Cole DK, Hassan B, Beck K, Gottlieb D, Ritchie DS, Seymour JF, Vari F, Crooks P, Burrows SR, Gandhi MK.

Clinical and Experimental Immunology. 2015 Sep 30. doi: 10.1111/cei.12716.

61) Distortion of the MHC class I binding groove to accommodate an insulin-derived 10-mer peptide.

Motozono C, Pearson JA, De Leenheer E, Rizkallah PJ, Beck K, Trimby A, Sewell AK, Wong FS and Cole DK.

Journal of Biological Chemistry. 2015. Jul 31;290(31):18924-33. doi: 10.1074/jbc.M114.622522. Epub 2015 Jun 17.

*featured on the journal cover.

60) More Tricks with Tetramers: A Practical Guide to Staining T cells with peptide-MHC Multimers.

Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, Holland CJ, Donia M, Godkin AJ, Cole DK, Straten PT, Peakman M, Svane IM, Sewell AK.

Immunology. 2015 Jun 16. doi: 10.1111/imm.12499. Impact factor: 3.1.

59) The ultimate mix and match: Making sense of HLA alleles and peptide repertoires.

Cole DK.

Immunology and Cell Biology. 2015 Mar 31. doi: 10.1038/icb.2015.40.

58) The Promise of γδ T cells and the γδ T cell Receptor for Cancer Immunotherapy.

Legut M, Cole DK, Sewell AK.

Cellular & Molecular Immunology. 2015 Apr 13. doi: 10.1038/cmi.2015.28.

57) The T cell antigen receptor: the Swiss Army knife of the immune system.

Attaf M, Legut M, Cole DK Sewell AK.

Clinical and Experimental Immunology. 2015 Mar 8. doi: 10.1111/cei.12622.

56) Naive CD8+ T-cell precursors display structured TCR repertoires and composite antigen-driven selection dynamics.

Neller MA, Ladell K, McLaren JE, Matthews KK, Gostick E, Pentier JM, Dolton G, Schauenburg AJ, Koning D, Costa IA, Watkins TS, Venturi V, Smith C, Khanna R, Miners K, Clement M, Wooldridge L, Cole DK, van Baarle D, Sewell AK, Burrows SR, Price DA and Miles JJ.

Immunology and Cell Biology. 2015 Mar 24. doi: 10.1038/icb.2015.17.

55) A Molecular Switch in Immunodominant HIV-1-Specific CD8 T-Cell Epitopes Shapes Differential HLA-Restricted Escape.

Cole DK, Kløverpris HN, Fuller A, Carlson J, Beck K, Schauenburg AJ, Rizkallah PJ, Buus S, Sewell AK, and Goulder P.

Retrovirology. 2015 Feb 20;12(1):20. doi: 10.1186/s12977-015-0149-5.

54) Tumor relapse following T cell receptor gene therapy is not due to loss of immunogenicity.

Straetemans T, Berrevoets C, Coccoris M, Treffers-Westerlaken E, Cole DK, Dardalhon V, Sewell A, Taylor N, Verweij J and Debets R.

Molecular Therapy. 2015 Feb;23(2):396-406. doi: 10.1038/mt.2014.215. Epub 2014 Nov 3.

53) Antibody crosslinking of peptide-MHC multimers reveals functional T-cells bearing extremely low affinity TCRs.

Tungatt K, Bianchi B, Crowther M, Powell W, Schauenburg AJ, Trimby A, Donia M, Skowera A, Miles JJ, Holland CJ, Cole DK, Godkin AJ, Peakman M, Straten PT, Svane IM, Sewell AK and Dolton G.

Journal of Immunology. 2015 Jan 1;194(1):463-74. doi: 10.4049/jimmunol.1401785. Epub 2014 Dec 1.

52) Structural basis for ineffective T-cell responses to MHC anchor residue-improved ‘heteroclitic’ peptides.

Madura M, Rizkallah PJ, Holland CJ, Fuller A, Bulek A, Godkin AJ, Schauenburg AJ, Sewell AK and Cole DK.

European Journal of Immunology. 2015 Feb;45(2):584-91. doi: 10.1002/eji.201445114. Epub 2014 Dec 28.

2014

51) Coreceptor-mediated Lck delivery to the TCR sets the antigen dwell-time threshold for central tolerance.

Stepanek O, Prabhakar AS, Osswald C, King CG, Bulek A, Naeher D, Beaufils-Hugo M, Abanto M, Galati V, Hausmann B, Lang R, Cole DK, Huseb E, Sewell AK, Chakraborty AK, and Palmer E.

Cell. 2014 Oct 9;159(2):333-45. doi: 10.1016/j.cell.2014.08.042. Epub 2014 Oct 2.

50) A distinct immunogenic region of GAD65 is naturally processed and presented by human islet cells to cytotoxic CD8 T-cells.

Knight RR, Dolton G, Kronenberg-Versteeg D, Eichmann M, Zhao M, Huang GC, Beck K, Cole DK, Sewell AK, Skowera A and Peakman M.

Clinical and Experimental Immunology. 2014 Aug 12. doi: 10.1111/cei.12436.

49) Comparison of peptide-Major Histocompatibility Complex tetramers and dextramers for staining of antigen-specific T-cells.

Dolton D, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, Kronenberg-Versteeg D, Akpovwa H, Pentier J, Holland CJ, Godkin AJ, Cole DK, Neller M, Miles JJ, Price DA, Peakman M and Sewell AK.

Immunology. 2014 Jul;177(1):47-63. doi: 10.1111/cei.12339.

48) Molecular basis of a dominant T-cell response to an HIV reverese transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01.

Motozono C, Kuse N, Sun X, Rizkallah PJ, Fuller A, Oka S, Takaguchi M, Sewell AK and Cole DK.

Journal of Immunology. 2014 Apr 1;192(7):3428-34. doi: 10.4049/jimmunol.1302667. Epub 2014 Mar 5.

2013

47) The versatility of the alpha/beta T-cell antigen receptor.

Bhati M, Cole DK, McCluskey J, Sewell AK, Rossjohn J.

Protein Science. 2013 Dec 24. doi: 10.1002/pro.2412. 2014 Mar;23(3):260-72. doi: 10.1002/pro.2412. Epub 2014 Jan 28.

46) TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions.

Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, Bulek AM, Fuller A, Akpovwa HJ, Pymm PG, Liddy N, Sami M, Li Y, Rizkallah PJ, Jakobsen BK, Sewell AK.

Journal of Biological Chemistry. 2014 Jan 10;289(2):628-38. doi: 10.1074/jbc.M113.522110. Epub 2013 Nov 6.

45) Cellular-level versus receptor-level response threshold hierarchies in T-cell activation.

van den Berg HA, Ladell K, Miners K, Laugel B, Llewellyn-Lacey S, Clement M, Cole DK, Gostick E, Wooldridge L, Sewell AK, Bridgeman JS, Price DA.

Frontiers in Immunology. 2013 Sep 5;4:250. doi: 10.3389/fimmu.2013.00250.

44) Re-directing CD4+ T cell responses with the flanking residues of MHC class II-bound peptides: the core is not enough.

Holland CJ, Godkin A and Cole DK.

Frontiers in Immunology. 2013 Jun 26;4:168. doi: 10.3389/fimmu.2013.00172.

43) Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.

Cole DK, Sami M, Scott DR, Rizkallah PJ, Borbulevych OY, Todorov PT, Moysey RK, Jakobsen BK, Boulter JM, Baker BM and Yi Li.

Frontiers in Immunology. 2013 Jun 26;4:168. doi: 10.3389/fimmu.2013.00168.

42) T-cell receptor specificity maintained by altered thermodynamics.

Madura F, Rizkallah PJ, Miles KM, Holland CJ, Bulek AM, Fuller A, Schauenburg AJ, Miles JJ, Liddy N, Sami M, Li Y, Hossain M, Baker BM, Jakobsen BK, Sewell AK and Cole DK.

Journal of Biological Chemistry. 2013 Jun 28;288(26):18766-75. doi: 10.1074/jbc.M113.464560. Epub 2013 May 22. Impact Factor 5.4.

2012

41) Peptide length determines the outcome of T cell receptor/peptide-MHCI engagement.

Ekeruche-Makinde J, Miles JJ, van den Berg HA, Skowera A, Cole DK, Dolton G, Schauenburg AJA, Tan MP, Pentier JM, Llewellyn-Lacey S, Miles KM, Bulek AM, Clement M, Williams T, Trimby A, Bailey M, Rizkallah P, Rossjohn J, Peakman M, Price DA, Burrows SR, Sewell AK and Wooldridge L.

Blood. 2012. Feb 14;121(7):1112-23. doi: 10.1182/blood-2012-06-437202. Epub 2012 Dec 18.. Impact Factor: 9.9.

40) Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.

Matthews P, Koyanagi M, Kloverpris H, Harndahl M, Stryhn A, Akahoshi T, Gatanaga H, Oka S, Molina C, Ponce H, Rios S, Cole D, Carlson J, Payne R, Ogwu A, Bere A, Ndung'u T, Gounder K, Chen F, Riddell L, Luzzi G, Shapiro R, Brander C, Walker B, Sewell AK, Teran G, Heckerman D, Hunter E, Buus S, Takiguchi M, and Goulder P.

Journal of Virology. 2012 Dec;86(23):12643-54. Epub 2012 Sep 12. Impact Factor: 5.4.

39) T Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting.

Cole DK, Ekeruche-Makinde J, Clement M, Edwards ESJ, Ladell K, Miles JJ, Matthew KK, Fuller A, Lloyd KA, Madura F, Dolton GM, Pentier J, Lissina A, Gostick E, Baxter TK, Baker BM, Rizkallah PJ, Price DA, Wooldridge L and Sewell AK.

Journal of Biological Chemistry. 2012 Oct 26;287(44):37269-81. doi:10.1074/jbc.M112.386409.

Epub 2012 Sep 5. Impact Factor: 5.4.

38) Minimal conformational plasticity enables TCR cross-reactivity to different HLA class II heterodimers.

Holland CJ, Rizkallah PJ, Vollers s, J. Calvo-Calle M, Madura M, Fuller A, Sewell AK, Stern LJ, Godkin A and Cole DK.

Scientific Reports. 2012 Sep 4;2:629.

37) Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon TCR avidity.

Knight RR, Kronenberg D, Zhao M, Huang GC, Bulek A, Wooldridge L, Cole DK, Sewell AK, Peakman M, Skowera A.

Diabetes. 2012 Aug 30. Epub ahead of print. Impact Factor: 8.3

36) The molecular determinants of CD8 co-receptor function.

Cole DK, Laugel B, Clement M, Price DA, Wooldridge L and Sewell AK.

Immunology. 2012 Oct 37;139-148. Epub 2012 Sep 04. Impact Factor: 3.3.

35) TCR/pMHC Optimized Protein crystallization Screen.

Bulek AM, Madura F, Fuller A, Holland CJ, Schauenburg AJ, Sewell AK, Rizkallah PJ, Cole DK.

Journal of Immunological Methods. 2012 Jun 15. Impact Factor: 2.3.

34) Modification of the C-terminal flanking-region of a universal influenza epitope alters CD4+ T-cell repertoire selection.

Cole DK, Gallagher K, Lemercier B, Holland CJ, Junaid S, HindleyJP, Wynn KW, Gostick E, Sewell AK, Gallimore A, Ladell K, Price DA, Gougeon M and Godkin A.

Nature Communications. 2012 Feb 7;3:665. Impact Factor: 7.4.

33) Structural basis of human β-cell killing by CD8+ T cells in Type 1 diabetes.

Cole DK, Bulek AM, Skowera S, Dolton G, Gras S, Madura F, Fuller A, Miles JJ, Gostick E, Price DA, Drijfhout JW, Knight RR, Huang GC, Lissin N, Molloy PE, Wooldridge L, Jakobsen BK, Rossjohn J, Peakman M, Rizkallah PJ and Sewell AK.

Nature Immunology.. 2012 Jan 15;13(3):283-9. Impact Factor: 25.7.*News and views in Nature Immunology and *voted in the top 2% of all biomedical publications in FS1000.

32) Structural and biophysical determinants of T-cell antigen recognition.

Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK.

Immunology. 2012 Jan;135(1):9-18. Epub 2011 Oct 04. Impact factor: 3.3.

2011

31) The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells.

Laugel B, Cole DK, Clement M, Wooldridge L, Price DA, Sewell AK.

Journal of Leukocyte Biology. 2011 Dec;90(6):1089-99. Epub 2011 Sep 27. Impact factor: 4.6.

30) Correlation of in situ mechanosensitive responses of the Moraxella catarrhalis adhesin UspA1 with fibronectin and receptor CEACAM1 binding.

Agnew C, Borodina E, Zaccai NR, Conners R, Burton NM, Vicary JA, Cole DK, Antognozzi M, Virji M, Brady RL.

Proceedings of the National Acadamy of Science U S A. 2011 Sep 13;108(37):15174-8. Epub 2011 Aug 29. Impact factor: 9.8.

29) Anti-CD8 antibodies can trigger T-cellleffector function in the absence of TCR engagement and improve pMHCI tetramer staining.

Clement M, Ladell K, Ekeruche J, Miles JJ, Edwards EJS, Dolton G, Schauenburg AJA, Cole DK, Lauder SN, Gallimore AM, Godkin AJ, Burrows SR, Price DA, Sewell AK, Wooldridge L.

Journal of Immunology. 2011 Jul 15;187 (2):654-63. Impact factor: 5.8. *Voted in the top 2% of all biomedical publications in FS1000.

28) Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no effect on complex stability.

Miles KM, Miles JJ, Madura M, Sewell AK and Cole DK.

Molecular Immunology. 2011 Jan;48(4):728-32. Impact factor: 3.2.

2010

27) Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection.

Cole DK, Miles JJ, Bulek A, Gostick E, Schauenburg AJA, Dolton G, Venturi V, Davenport MP, Tan MP, Burrows SR, Wooldridge L, Price DA, Rizkallah PJ and Sewell AK.

PLOS Pathogens. 2010 Nov 18;6(11):e1001198. Impact factor: 9.1.

26) Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T-cell recognition.

Cole DK, Edwards EJ, Wynn KK, Clement M, Miles JJ, Ladell K, Ekeruche J, Gostick E, Adams K, Skowera S, Peakman M, Wooldridge L, Price DA and Sewell AK.

Journal of Immunology. 2010 Aug 15;185(4):2600-10. Impact factor: 5.8. *Voted in the top 2% of all biomedical publications in FS1000.

25) MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.

Wooldridge L, Clement M, Lissina A, Edwards E, Hewitt RE, Gostick E, Cole DK, Debets R, Price DA and Sewell AK.

Journal of Immunology. 2010 Apr 1;184(7):3357-66. Impact factor: 5.8

2009

24) T cell receptor crossreactivity directed by antigen-dependent molecular motion in a peptide/MHC complex.

Borbulevych OY,. Piepenbrink KH, Gloor BE, Scott DR, Sommese RF, Cole DK, Sewell AK, and Baker BM.

Immunity. 2009 Dec 18;31(6):885-96. Impact factor: 20.6. *Voted in the top 2% of all biomedical publications in FS1000.

23) ELISPOT and functional T cell analyses using HLA mono-specific target cells.

Horlock C, Stott B, Dyson J, Ogg G, McPherson T, Jones L, Sewell A, Wooldridge L, Cole DK, Stebbing J, Savage P.

Journal of Immunological Methods. 2009 Oct 31;350(1-2):150-60. Epub 2009 Sep 1. Impact factor: 3.5.

22) Peptide-MHC dimensions control proximal kinase-phosphatase balance during T cell activation.

Choudhuri K, Parker M, Milicic A, Cole DK, Shaw MK, Sewell AK, Stewart-Jones G, Dong T, Gould KG, and van der Merwe PA.

Journal of Biological Chemistry. 2009 Sep 18;284(38):26096-105. Epub 2009 Jul 23. Impact factor: 5.6.

21) Germline-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, Gao GF, Jakobsen BK, Sewell AK.

Journal of Biological Chemistry. 2009 Oct 2;284(40):27281-9. Epub 2009 Jul 15. Impact factor: 5.6.

20) Tricks with Tetramers: How to get the most from multimeric peptide-MHC.

Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA and Sewell AK. Impact factor: 3.3.

Immunology. 2009 Feb; 126(2): 147-64.

2008

19) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.

Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL.

Nature Medicine. 2008 Dec;14(12):1390-5. Impact factor: 27.3.

18) Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.

Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Lissina A, Gostick E, Cole DK, Wooldridge L, van den Berg HA, Bornstein E, Hensel NF, Douek DC, Roederer M, Sewell AK, Barrett AJ, Price DA.

Journal of Immunological Methods. 2008 Sep 30;338(1-2):31-9. Impact factor: 3.5.

17) T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding.

Cole DK, Dunn SM, Sami M, Boulter JM, Jakobsen BK, Sewell AK.

Molecular Immunology. 2008 May;45(9):2700-9.Impact factor: 3.2.

2007

16) Different T cell receptor affinity thresholds and CD8 coreceptor dependency govern cytotoxic T lymphocyte activation and tetramer binding properties.

Laugel B, van den Berg HA, Gostick E, Cole DK, Wooldridge L, Boulter JM, Milicic A, Price DA, Sewell AK.

Journal of Biological Chemistry. 2007: 282(33): 23799-810. Impact factor: 5.6.

15) Human TCR-Binding Affinity is Governed by MHC Class Restriction.

Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK.

Journal of Immunology. 2007: 178(9): 5727-34. Impact factor: 5.8.

14) Functional and biophysical characterization of an HLA A*6801-restricted HIV-specific T cell receptor.

Gostick E, Cole DK, Hutchinson SL, Wooldridge L, Tafuro S, Laugel B, Lissina A, Oxenius A, Boulter JM, Price DA, Sewell AK.

European Journal of Immunology. 2007: 37(2): 479-86. Impact factor: 5.1.

13) Computational design and crystal structure of an enhanced affinity mutant human CD8 alpha/alpha co-receptor.

Cole DK, Rizkallah PJ, Boulter JM, Sami M, Vuidepot AL, Glick M, Gao F, Bell JI, Jakobsen BK, Gao GF.

Proteins. 2007: 67(1): 65-74. Impact factor: 3.6.

2006

12) Crystal structure of HLA-A*2402 complexed with a telomerase peptide.

Cole DK, Rizkallah PJ, Gao F, Watson, NI, Boulter JM., Bell JI., Sami M, Gao GF, Jakobsen BK.

European Journal of. Immunology. 2006: 36: 170-9. Impact factor: 5.1.

2005

11) Crystallisation and preliminary X-ray structural studies of a high affinity CD8alpha/alpha co-receptor to pMHC.

Cole DK, Rizkallah PJ, Boulter JM., Sami M, Vuidepot AL, Glick M, Gao F, Bell JI., Jakobsen BK, Gao GF.

ACTA F. 2005, F61, 0-0. Impact factor: 0.6.

10) Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.

Wang HW, Cole D, Jiang WZ, Jin HT, Fu N, Chen ZL, Jin NY.

Clinical and Experimental Immunology. 2005: 141: 72-80. Impact factor: 3.3.

2004

9) CD8: Adhesion molecule, co-receptor and immuno-modulator.

Cole DK, Gao GF.

Cellular & Molecular Immunology. 2004: 2: 81-88. Impact factor: 3.5.

8) Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus.

Xu Y, Zhu J, Liu Y, Lou Z, Yuan F, Liu Y, Cole DK, Ni L, Su N, Qin L, Li X, Bai Z, Bell JI, Pang H, Tien P, Gao GF, Rao Z.

Biochemistry. 2004: 43: 14064-71. Impact factor: 3.8.

7) Construct design, biophysical, and biochemical characterization of the fusion core from mouse hepatitis virus (a coronavirus) spike protein.

Xu Y, Cole DK, Lou Z, Liu Y, Qin L, Li X, Bai Z, Yuan F, Rao Z, Gao GF.

Protein Expression and Purification. 2004: 38: 116-22. Impact factor: 3.2.

6) Biochemical, biophysical and preliminary X-ray crystallographic analyses of the fusion core of Sendai virus F protein.

Wang X, Xu Y, Cole DK, Lou Z, Liu Y, Rao Z, Wang M, Gao GF.

Acta Crystallography D Biological Crystallography. 2004: 60: 1632-5. Impact factor: 4.8.

5) Complex assembly, crystallization and preliminary X-ray crystallographic studies of MHC H-2Kd complexed with an HBV-core nonapeptide.

Zhou M, Xu Y, Lou Z, Cole DK, Li X, Liu Y, Tien P, Rao Z, Gao GF.

Acta Crystallography D Biological Crystallography. 2004: 60: 1473-5. Impact factor: 4.8.

4) SARS coronavirus induces apoptosis in Vero E6 cells.

Yan H, Xiao G, Zhang J, Hu Y, Yuan F, Cole DK, Zheng C, Gao GF.

Journal of Medical Virology. 2004: 73: 323-31. Impact factor: 3.4.

3) Crystallization and preliminary crystallographic analysis of the fusion core from two new zoonotic paramyxoviruses, Nipah virus and Hendra virus.

Xu Y, Lou Z, Liu Y, Cole DK, Su N, Qin L, Li X, Bai Z, Rao Z, Gao GF.

Acta Crystallography D Biological Crystallography. 2004: 60: 1161-4. Impact factor: 4.8.

2) Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors.

Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF.

Biochemical and Biophysical Research Communications. 2004: 18: 283-8. Impact factor: 3.3.

1) Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses.

Xu Y, Gao S, Cole DK, Zhu J, Su N, Wang H, Gao GF, Rao Z.

Biochemical and Biophysical Research Communications. 2004: 315: 664-70. Impact factor: 3.3.